Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07489885
Recruiting Phase 2

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885 · tracked via the Priya Life Science USA tracker
Sponsor
InventisBio Co., Ltd
Phase
Phase 2
Started
2026-06-03
Last updated
2026-07-09

Condition(s) studied

Psoriasis

Investigational drug(s) / intervention(s)

D-2570 Tablet →Placebo Tablets

D-2570 Tablet: Active Treatment

Placebo Tablets: Identical Tablet

Study summary

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent * Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3. * Within normal ranges of laboratory assessments Exclusion Criteria: * Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Primary outcome measure(s)

  • Improvement in PASI-90 — Assessment completed after 12 weeks of treatment/placebo
    Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

Trial sites (20)

FacilityCityRegionStatus
Study Center Birmingham Alabama Recruiting
Study Center Phoenix Arizona Not Yet Recruiting
Study Center Chula Vista California Recruiting
Study Center Fountain Valley California Not Yet Recruiting
Study Center Fremont California Not Yet Recruiting
Study Center Los Angeles California Not Yet Recruiting
Study Center Los Angeles California Not Yet Recruiting
Study Center San Diego California Not Yet Recruiting
Study Center Fort Lauderdale Florida Not Yet Recruiting
Study Center Miramar Florida Not Yet Recruiting
Study Center Ocala Florida Not Yet Recruiting
Study Center Tampa Florida Not Yet Recruiting
Study Center Sandy Springs Georgia Not Yet Recruiting
Study Center Savannah Georgia Not Yet Recruiting
Study Center Idaho Falls Idaho Not Yet Recruiting
Study Center Clarksville Indiana Not Yet Recruiting
Study Center Louisville Kentucky Not Yet Recruiting
Study Center Mayfield Heights Ohio Not Yet Recruiting
Study Center Philadelphia Pennsylvania Not Yet Recruiting
Study Center San Antonio Texas Recruiting

More InventisBio Co., Ltd trials in the USA

Healthy Volunteer Study Active, not recruiting

Other trials for the same condition

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Active, not recruiting
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis Recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Active, not recruiting
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07489885 on ClinicalTrials.gov ↗ ← All trials in the USA